Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.

Alimentary pharmacology & therapeutics - 1 Feb 2005

Sheu B-S, Kao A-W, Cheng H-C, Hunag S-F, Chen T-W, Lu C-C, Wu J-J

Abstract excerpt

AIM: To determine whether an increased dosage of esomeprazole 40 mg twice daily in triple therapy improved the Helicobacter pylori eradication rate for patients with different genotypes of S-mephenytoin 4'-hydroxylase (CYP2C19). METHODS: Two hundred H. pylori-infected dyspeptic patients were randomized to receive clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily plus either omeprazole 20 mg or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amoxicillin
Share to Anti-Ulcer Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clarithromycin

Share to Cytochrome P-450 CYP2C19

Share to Drug Administration Schedule

Share to Gastric Mucosa

Share to Mixed Function Oxygenases

Share to Omeprazole

Source

Identifiers

PMID: 15691303
DOI: 10.1111/j.1365-2036.2005.02281.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.PMID 15691303Read ↗

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype.Semantic proximity Read ↗

CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.Semantic proximity Read ↗

First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.Semantic proximity Read ↗

Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole.Semantic proximity Read ↗

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.Semantic proximity Read ↗

Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer.Semantic proximity Read ↗

Influence of CYP2C19 functional polymorphism on Helicobacter pylori eradication.Semantic proximity Read ↗

Role of omeprazole dosage and cytochrome P450 2C19 genotype in patients receiving omeprazole-amoxicillin dual therapy for Helicobacter pylori eradication.Semantic proximity Read ↗

Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens.Semantic proximity Read ↗

Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance.Semantic proximity Read ↗

Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori.Semantic proximity Read ↗

The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.